Page 4 - Deals Andm Amp A News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Deals andm amp a. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Deals Andm Amp A Today - Breaking & Trending Today

Data credibility voids Olympus' $370M buyout of Taewoong Medical

Another med-tech acquisition was wiped off the charts after Japan’s Olympus Corp. rescinded the acquisition of South Korean medical device firm Taewoong Medical Co. Ltd. on March 7, after finding “data integrity issues” related to Taewoong’s products. ....

South Korea , South Korean , Taewoong Medical Co , Japan Olympus Corp , Taewoong Medical , Bioworld Medtech , Olympus Corp , Taewoong Medical Co Ltd , Nitis Gi Stent , Deals Andm Amp A , Asia Pacific , Medical Devices ,

Alteogen names MSD as partner in revised, potential $3.8B+ deal

In a surprise reveal that propelled stocks by 25%, Alteogen Inc., of Daejeon, South Korea, named MSD International Business GmbH as its counterpart in a near-$4 billion technology transfer agreement inked in 2020, while upping terms of the deal. ....

South Korea , Taejon Gwangyoksi , International Business Gmb , Alteogen Inc , Business Gmbh , Alteogen Inc , Msd International Business Gmbh , Merck Co Amp Inc , Human Recombinant Hyaluronidase Enzyme , Deals Andm Amp A , Asia Pacific , Bioworld Asia ,

Rigel takes on US marketing of Blueprint's Gavreto

Blueprint Medicines Corp. found a new U.S. commercialization home for Gavreto (pralsetinib) through an agreement with Rigel Pharmaceuticals Inc. potentially worth $117.5 million, now that Roche Holding AG has relinquished all rights. ....

Blueprint Medicines Corp , Roche Holding , Rigel Pharmaceuticals Inc , Blueprint Medicines , Rigel Pharmaceuticals , Blueprint Medicines Corp , Rigel Pharmaceuticals Inc , Roche Holding Ag , Non Small Cell Lung Cancer , Deals Andm Amp A , Ret Inhibitor , Medullary Thyroid Cancer ,

Adagio speeds up financing rhythm with $42M SPAC deal

The slow pace of financing in med-tech appears to have stimulated cardiac arrhythmia technology developer Adagio Medical Inc. to turn to a special purpose acquisition company (SPAC) in a type of deal that has all but vanished in the last year. The company signed an agreement with Arya Sciences Acquisition Corp. IV to combine in a reverse merger deal that will result in Adagio’s listing on Nasdaq under “ADGM.” ....

Adagio Medical Inc , Arya Sciences Acquisition Corp , Adagio Medical , Arya Sciences Acquisition , Bioworld Medtech , Adagio Medical Inc , Pulsed Field Ablation , Ultra Low Temperature Cryoablation , Atrial Fibrillation , Ventricular Tachycardia , Deals Andm Amp A ,

Astellas' Xyphos teams with Kelonia on cancer drugs in $800M deal

San Francisco-based Xyphos Biosciences Inc. is pooling technology platforms with Boston’s Kelonia Therapeutics Inc. in a novel immuno-oncology (I-O) drug discovery deal that could fetch more than $800 million. Xyphos and Kelonia will collaborate to develop a maximum of two in vivo CAR T-cell therapy programs, utilizing both Kelonia’s in vivo gene placement system called iGPS and Xyphos’ Accel technology platform. ....

Boston Kelonia Therapeutics Inc , San Xyphos Biosciences Inc , San Francisco Based Xyphos Biosciences , Kelonia Therapeutics , Xypho Accel , Xyphos Biosciences Inc , Kelonia Therapeutics Inc , Immuno Oncology , Drug Discovery , Astellas Pharma Inc , Cart Cell Therapy , Deals Andm Amp A , Asia Pacific ,